Melbourne-based Telix Pharmaceuticals (ASX:TLX), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on 'molecularly-targeted radiation' (MTR), has announced a research collaboration agreement with German-based Merck Healthcare KGaA.
In a statement, Telix said under the terms of the agreement it will collaborate with Merck to conduct combination studies with several of the German company's molecules in combination with two of its MTR therapeutic programs.
The agreement provides Telix with access to Merck molecules for use in a mutually agreed research plan to evaluate combination efficacy in models relevant to clinical translation.
"The agreement includes industry-standard collaborative intellectual property provisions. No Telix intellectual property rights have been granted to MRK at this time," said Telix.
It added that any follow-on clinical collaboration is subject to the outcomes of the initial research and will be governed by a separate clinical trial agreement to be agreed between the parties.
"As the research is commercial-in-confidence, the molecules and oncology focus areas are not disclosed at this time," it concluded.